For research use only. Not for therapeutic Use.
Mc-Val-Cit-PAB-Gefitinib chloride（Cat No.:I041414）is a conjugate that combines the anticancer drug Gefitinib, a selective epidermal growth factor receptor (EGFR) inhibitor, with a peptide linker (Mc-Val-Cit-PAB). The Mc-Val-Cit sequence is a cleavable linker designed to release Gefitinib specifically in targeted cells, such as cancer cells, where the enzyme activity (e.g., cathepsins) cleaves the linker. This conjugation improves the drug’s specificity, reducing side effects associated with conventional chemotherapy. The compound shows promise in drug delivery systems and targeted cancer therapies, enhancing the precision and effectiveness of Gefitinib in treating tumors with EGFR mutations.
| Synonyms | N-[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-[[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-1-ium-1-yl]methyl]anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-6-(2,5-dioxopyrrol-1-yl)hexanamide;chloride |
| Molecular Formula | C50H63Cl2FN10O9 |
| Purity | ≥95% |
| IUPAC Name | N-[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-[[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-1-ium-1-yl]methyl]anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-6-(2,5-dioxopyrrol-1-yl)hexanamide;chloride |
| InChI | InChI=1S/C50H62ClFN10O9.ClH/c1-32(2)46(59-43(63)10-5-4-6-21-62-44(64)17-18-45(62)65)49(67)58-39(9-7-19-54-50(53)68)48(66)57-34-13-11-33(12-14-34)30-61-31-55-47(56-35-15-16-38(52)37(51)27-35)36-28-42(41(69-3)29-40(36)61)71-24-8-20-60-22-25-70-26-23-60;/h11-18,27-29,31-32,39,46H,4-10,19-26,30H2,1-3H3,(H6,53,54,57,58,59,63,66,67,68);1H/t39-,46-;/m0./s1 |
| InChIKey | GXZFEBRMATXINW-POBFPDAXSA-N |
| SMILES | CC(C)[C@@H](C(=O)N[C@@H](CCCNC(=O)N)C(=O)NC1=CC=C(C=C1)C[N+]2=CN=C(C3=CC(=C(C=C32)OC)OCCCN4CCOCC4)NC5=CC(=C(C=C5)F)Cl)NC(=O)CCCCCN6C(=O)C=CC6=O.[Cl-] |
